Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial

Battelino, Tadej; Rasmussen, Michael Højby; De Schepper, Jean; Zuckerman-Levin, Nehama; Gucev, Zoran; Sävendahl, Lars; Schwitzgebel Luscher, Valérie; Zumsteg, Urs; NN8640-4042 Study Group

doi:10.1111/cen.13409

Scientific article

English

Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial

ContributorsBattelino, Tadej; Rasmussen, Michael Højby; De Schepper, Jean; Zuckerman-Levin, Nehama; Gucev, Zoran; Sävendahl, Lars; Schwitzgebel Luscher, Valérie; Zumsteg, Urs; NN8640-4042 Study Group

Published inClinical Endocrinology, vol. 87, no. 4, p. 350-358

Publication date2017

Abstract

To evaluate the safety, local tolerability, pharmacodynamics and pharmacokinetics of escalating single doses of once-weekly somapacitan, a reversible, albumin-binding GH derivative, vs once-daily GH in children with GH deficiency (GHD).

Keywords

Child
Child
Preschool
Dwarfism
Pituitary/blood/drug therapy
Female
Growth Hormone/analogs & derivatives/pharmacokinetics/therapeutic use
Human Growth Hormone/analogs & derivatives/blood/deficiency
Humans
Insulin-Like Growth Factor Binding Protein 3/blood
Insulin-Like Growth Factor I/metabolism
Male

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de pédiatrie, gynécologie et obstétrique

Research groups

Diabète et métabolisme (178)

Citation (ISO format)

BATTELINO, Tadej et al. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial. In: Clinical Endocrinology, 2017, vol. 87, n° 4, p. 350–358. doi: 10.1111/cen.13409

Article (Accepted version)

Identifiers

PID : unige:108162
DOI : 10.1111/cen.13409
PMID : 28656605

Journal ISSN0300-0664

465views

0downloads

Creation20/09/2018 16:55:00

First validation20/09/2018 16:55:00

Update15/03/2023 08:40:42

Status update15/03/2023 08:40:41

Last indexation31/10/2024 11:07:46

Archive ouverte UNIGE

Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial

To evaluate the safety, local tolerability, pharmacodynamics and pharmacokinetics of escalating single doses of once-weekly somapacitan, a reversible, albumin-binding GH derivative, vs once-daily GH in children with GH deficiency (GHD).

Technical informations